Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 4/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.42 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.42 |
| ▸ | TTBK1 | Q5TCY1 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | PIKFYVE | Q9Y2I7 | 4/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 6/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13768258 | 0.85 | TTBK1 (0.43) | PAK4PAK1PKN1TTBK1TDP1 | |
| SCHEMBL7851731 | 0.79 | HTT (0.41) | PAK4PAK1PKN1TTBK1PIKFYVE | |
| SCHEMBL278879 | 0.77 | TTBK1 (0.41) | PAK4PAK1PKN1TTBK1ALDH1A1 | |
| SCHEMBL14282689 | 0.77 | TTBK1 (0.41) | PAK4PAK1PKN1TTBK1ALDH1A1 | |
| SCHEMBL12391039 | 0.76 | ASIC3 (0.50) | TTBK1ALDH1A1PIKFYVEASIC3MAPT | |
| SCHEMBL11209803 | 0.75 | ASIC3 (0.39) | PAK4PAK1PKN1TTBK1PIKFYVE | |
| SCHEMBL14949230 | 0.75 | PIKFYVE (0.45) | PAK4PAK1PKN1TTBK1PIKFYVE | |
| SCHEMBL3448180 | 0.75 | APP (0.54) | PAK4PAK1PKN1TTBK1PIKFYVE | |
| SCHEMBL3771763 | 0.73 | PTGES2 (0.45) | PAK4PAK1PKN1TTBK1PIKFYVE | |
| SCHEMBL30092382 | 0.73 | MAP3K14 (0.45) | PAK4PAK1PKN1TTBK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697737-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110071145-A1 | Raf Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7846959-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080009488-A1 | Raf Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| EP-1751124-A2 | RAF MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005112932-A2 | RAF MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009488-A1 | Raf Modulators and Methods of Use | BRAF, RAF1, ARAF | PAK4 46/4885PAK1 56/4885PKN1 789/4885 |
| US-20110071145-A1 | Raf Modulators And Methods Of Use | BRAF, RAF1, ARAF | PAK4 50/4885PAK1 52/4885PKN1 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.